Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Primary Objectives:

* Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
* Randomized Phase 3 Part: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to lenalidomide and dexamethasone in subjects with high-risk SMM

Secondary Objectives:

Safety run-in Part:

* To assess overall response rate (ORR)
* To assess duration of response (DOR)
* To assess minimal residual disease (MRD) negativity in participants achieving very good partial response (VGPR) or complete response (CR)
* To assess time to diagnostic (SLiM CRAB) progression or death
* To assess time to first-line treatment for multiple myeloma (MM)
* To assess the potential immunogenicity of isatuximab
* Impact of abnormal chromosomal subtype on participant outcome

Randomized Phase 3 Part:

Key Secondary Objectives:

To compare between the arms

* MRD negativity
* Sustained MRD negativity
* Second progression-free survival (PFS2)
* Overall survival

Other Secondary Objectives:

To evaluate in both arms

* CR rate
* ORR
* DOR
* Time to diagnostic (SLiM CRAB) progression
* Time to biochemical progression
* Time to first-line treatment for MM
* Impact of abnormal chromosomal subtype on participant outcome
* Safety and tolerability
* Pharmacokinetics (PK)
* Potential of isatuximab immunogenicity
* Clinical outcome assessments (COAs)
Plasma Cell Myeloma
DRUG: Isatuximab SAR650984|DRUG: Lenalidomide|DRUG: Dexamethasone|DRUG: Montelukast or equivalent|DRUG: Acetaminophen|DRUG: Diphenhydramine or equivalent|DRUG: Methylprednisolone or equivalent
Number of participants with Treatment-emergent adverse events (AEs) and serious adverse events- Safety Run-in Part, Up to approximately 63 months|Plasma concentration of isatuximab during the treatment period - Safety Run-in Part, After first infusion from Cycle 1 Day 1 to Day 28 in safety run-in part|Receptor density/receptor occupancy Safety Run-in Part, Change in CD38 receptor occupancy from baseline, Baseline to Cycle 2 Day 1 (each cycle is 28 days)|Progression-free survival (PFS) Randomized Phase 3 Part, PFS defined as the time from randomization to MM (SLiM CRAB criteria) or other related conditions based on independent review committee (IRC) assessment according to 2014 International Myeloma Working Group (IMWG) criteria or death from any cause, whichever happens first, Up to approximately 114 months
Overall Response Rate (ORR)- Safety Run-in Part, ORR defined as the proportion of participants with best overall response (BOR) recorded as partial response (PR) or better according to 2016 IMWG criteria, Up to approximately 63 months|Duration of Response (DOR) - Safety Run-in Part, DOR defined as the time from the date of the first response to date of first progressive disease (PD) or death, whichever happens first., Up to approximately 63 months|Minimal residual disease (MRD) negativity -Safety Run-in Part, MRD negativity defined as the proportion of participants for whom MRD is negative in participants achieving very good partial response (VGPR) or above., Up to approximately 36 months|Time to diagnostic (SLiM CRAB) progression or death - Safety Run-in Part, Time to diagnostic (SLiM CRAB) progression or death defined as the time from the date of the first study intervention administration to diagnosis of SLiM CRAB or other related conditions progression or death from any cause, whichever happens first., Up to approximately 63 months|Time to first-line treatment for multiple myeloma (MM) - Safety Run-in Part, Time to first-line treatment for MM defined as the time from the date of the first study intervention administration to first-line treatment for MM., Up to approximately 63 months|Number of participants with anti-drug antibodies (ADA) against isatuximab- Safety Run-in Part, Up to approximately 63 months|PFS in participants with chromosomal abnormalities - Safety Run-In Part, Association of chromosomal abnormalities with survival outcomes, Up to approximately 63 months|Overall Survival (OS) in participants with chromosomal abnormalities - Safety Run-In Part, Association of chromosomal abnormalities with survival outcomes, Up to approximately 63 months|Minimal residual disease (MRD) negativity - Randomized Phase 3 Part, MRD negativity defined as the proportion Number of participants for whom MRD is negative in participants achieving VGPR or above., Up to approximately 36 months|Sustained MRD negativity - Randomized Phase 3 Part, Sustained MRD negativity defined as the proportion of participants for whom MRD is negative during a minimum period of one year., Up to approximately 36 months|Second PFS (PFS2) - Randomized Phase 3 Part, PFS2 defined as the time from the date of randomization to the date of first documentation of PD (as reported by the Investigator) after initiation of further treatment for MM or the date of death from any cause, whichever happens first, Up to approximately 144 months|OS - Randomized Phase 3 Part, OS defined as the time from date of randomization to death from any cause., Up to approximately 114 months|Complete response (CR) rate - Randomized Phase 3 Part, Percentage of participants with a CR (or better \[stringent CR (sCR)\]) as defined by 2016 IMWG response criteria, assessed by an IRC based on central laboratory values., Up to approximately 114 months|Overall Response Rate (ORR) - Randomized Phase 3 Part, ORR is defined as the proportion of participants with BOR recorded as PR or better according to the 2016 IMWG criteria, assessed by an IRC based on central laboratory values., Up to approximately 114 months|Duration of response (DOR) - Randomized Phase 3 Part, DOR is defined as the time from the date of the first IRC determined response to the date of first IRC PD, or death, whichever happens first., Up to approximately 114 months|Time to diagnostic (SLiM CRAB) progression - Randomized Phase 3 Part, Time to diagnostic (SLiM CRAB) progression defined as the time from randomization to the date of diagnosis of SLiM CRAB progression based on IRC assessment., Up to approximately 114 months|Time to biochemical progression - Randomized Phase 3 Part, Time to biochemical progression defined as the time from randomization to the date of biochemical progression based on IRC assessment., Up to approximately 114 months|Time to first-line treatment for MM- Randomized Phase 3 Part, Time to first-line treatment for MM defined as the time from randomization to first-line treatment for MM, Up to approximately 144 months|PFS in participants with chromosomal abnormalities - Randomized Phase 3 Part, Association of chromosomal abnormalities with survival outcomes., Up to approximately 114 months|OS in participants with chromosomal abnormalities - Randomized Phase 3 Part, Association of chromosomal abnormalities with survival outcomes., Up to approximately 144 months|Number of participants with Treatment-emergent adverse events (AEs) and serious adverse events - Randomized Phase 3 Part, Up to approximately 144 months|Plasma concentration of isatuximab (Ctrough)- Safety Run-in and Randomized Phase 3 Part, Ctrough defined as concentration observed just before treatment administration during repeated dosing after IV administration, Baseline to Cycle 2 Day 1 (each cycle is 28 days)|Concentration observed at the end of intravenous infusion.(Ceoi)- Safety Run-in Part, Day 1 of Cycle 1 to 4|Number of participants with Incidence of anti-drug antibodies (ADA) against isatuximab- Randomized Phase 3 Part, Up to approximately 144 months|European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 - Randomized Phase 3 Part, The EORTC Multiple Myeloma Module (QLQ-C30) will be used to assess cancer-specific health related quality of life (HRQL), disease and treatment related symptoms and impact of symptoms. Mean change from baseline scores will be assessed, with responses ranging from 1=not at all to 4=very much or 1=very poor to 7=excellent; higher scores represent a better level of physical functioning, Baseline to follow-up (up to approximately 114 months)|EORTC QLQ-MY20 - Randomized Phase 3 Part, The EORTC Multiple Myeloma Module (QLQ-MY20) will be used to measure myeloma-specific HRQL, disease and treatment related symptoms and impact of symptoms. Mean change from baseline in scores will be assessed using a 4-point scale, with responses ranging from 1=not at all to 4=very much; higher scores represent better perspectives of the future and higher level of symptomatology, Baseline to follow-up (up to approximately 114 months)|EQ-5D-5L - Randomized Phase 3 Part, The EQ-5D-5L will be used to assess health status and health utility. Mean change from baseline scores will be assessed from 5 items, with responses ranging from 'no' to 'extreme problems'; health state utility values (HSUVs) are generated by multiplying the item scores by country specific value sets; health status is assessed via a VAS; higher scores = higher HSUV/health status, Baseline to follow-up (up to approximately 114 months)|Randomized Phase 3: HRUPQ - Randomized Phase 3 Part, Mean change from baseline in Health resource utilization and productivity questionnaire (HRUPQ) scores. HRUPQ will assess health care resource utilization of HRSM and the impact of high risk smoldering multiple myeloma (HRSMM) on employment/work; higher scores = greater impact on work/productivity, resources., Baseline to follow-up (up to approximately 114 months)|Patient's Qualitative Assessment of Treatment Version 2 (PQAT-v2) - Randomized Phase 3 Part, PQAT-v2 will be used to assess participant-perceived advantages and disadvantages of treatment. Patient's qualitative assessment of treatment will be assessed using a 10 point VAS/NRS scale with response anchors of 'not beneficial at all' to 'extremely beneficial'; higher scores represent greater patient-perceived benefits of treatment, End of treatment (up to approximately 3 year)
Study duration is expected to be approximately 12 years, including a 42-day screening period, followed by an up to 36-month treatment period, and a follow-up period of approximately 9 years.